All News
Novel and Emerging Therapies in Psoriatic Arthritis
Recent advancements in targeted therapies, including selective inhibitors of key inflammatory pathways, offer promising outcomes for patients with active psoriatic arthritis (PsA). At ACR 2024, there have been further developments in novel therapies in PsA.
Read Article
Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read Article
SELECTing the right patients: upadacitinib in GCA
Dr. Brian Jaros reports on abstract 1695, presented at #ACR24.
https://t.co/x8lLTviOKk https://t.co/yXwwrdgIyu
Dr. John Cush RheumNow ( View Tweet)
How New Medications are Reframing Imaging Abnormalities in axSpA
Bimekizumab (BKZ), a monoclonal antibody targeting IL-17A and IL-17F, was evaluated in the BE MOBILE 1 and 2 trials for non-radiographic and radiographic axSpA, respectively. It showed significant clinical… https://t.co/wJYh5XCVfw https://t.co/qZ2MnGVXXG
Dr. John Cush RheumNow ( View Tweet)
💊Litifilimab- another new molecule for SLE
Anti BDCA2 🎯
In cutaneous lupus👉
👉Decrease CLASI score
👉Decrease IFN induced MxA expression
#ACR2024 #ACRAmbassador https://t.co/AeJOGhVXIR
Ritasman Baisya RitasmanB ( View Tweet)
SELECT-GCA: Efficacy and Safety of Upadacitinib
Dr. Richard Conway discusses abstract 0770, presented at #ACR24
https://t.co/C9HZIMP9JK https://t.co/zVhFAfLBQe
Dr. John Cush RheumNow ( View Tweet)
JAK inhibitors in GCA?
We have a phase 3 trial in giant cell arteritis back on the opening day plenary stage. The SELECT-GCA study, looking at upadacitinib in GCA, was scheduled to anchor the #ACR24 opening plenary for a reason - it is highly notable and badly needed.… https://t.co/aJ3uao1wD7 https://t.co/6ao2OoODHg
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Agonists Show Promise in Slowing Kidney Disease in Lupus Nephritis
Glucagon-like peptide-1 receptor agonists (GLP-1Ra) have transformed the treatment landscape for type 2 diabetes and obesity. #ACR24
https://t.co/6QqEH8X2VJ https://t.co/Ch2i9zZYii
Dr. John Cush RheumNow ( View Tweet)
JAKi in inflammatory myositis? #ACR24 will showcase nearly 3000 abstracts. With the expanding use of JAK inhibitors, there will be some interesting presentations for off label use. There have been some uncontrolled data that tofacitinib reduced inflammatory myositis disease… https://t.co/SnqvElwk0B https://t.co/A5mJbpmB5P
Dr. John Cush RheumNow ( View Tweet)
Finding the Right Combination Therapy in RA
Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu
Dr. John Cush RheumNow ( View Tweet)
#Ianalumab
300 mg sc q monthly
B cell depleted and changes BAFF signalling
👇⬇️IFN
May be promising in #lupus #SLE
+data in primary #Sjogrens
ACR24 @RheumNow @ACRheum
Abst#2425
Needs Phase3
➡️I suspect safer than CAR T and Bispecific T cell engagers but
? ⬇️efficacy
Janet Pope Janetbirdope ( View Tweet)
ACR24 take homes
➡️#Inflammatory #myositis
#Upadacitinib improved MDA5 ILD
#Baricitinib 4mg/d good in myositis delayed start #RCT
#Tofacitinb ➡️help for skin, calcinosis, rash in case series
➡️RCT ongoing
JAKi is ‘jacked’ in muscles 💪🏿
#ACR24 @RheumNow @ACRheum
1731 0348
Janet Pope Janetbirdope ( View Tweet)
Late breaking abstract L17
CAR-NK Therapy for Refractory SLE.
In a trial of 20 severe SLE patients:
- 75% achieved LLDAS, 50% achieved DORIS remission at 6 months
- B cell reconstitution: 2–3 months post-treatment
- Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In Vivo CAR T Cell Therapy.
A single intralymphatic injection of VivoVec™ particles:
- Generates functional CAR T cells in vivo
- Achieves complete B cell depletion in NHPs without lymphodepletion
- Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1
Bella Mehta bella_mehta ( View Tweet)
Hydralazine - known culprit of drug-induced AAV
How does hydral (H) AAV differ from primary (1) AAV?
💥 High dual positivity MPO/PR3
💥 DAH / pleuritis more common in H-AAV
💥 ENT, constitutional, nervous, ILD in 1-AAV
💥 More 6mo remission in H-AAV
@rheumnow #ACR24 Abst 2496
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity.
Mechanism? NAC reduces rapamycin (mTOR) activation.
Common AEs: nausea, vomiting
@RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP
Links:
sheila RHEUMarampa ( View Tweet)
In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II
#ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe
Jiha Lee JihaRheum ( View Tweet)
SELECT-GCA suggests JAKis may be the new kid on the block
Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select.
https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY
Dr. John Cush RheumNow ( View Tweet)
LEVI-04 a novel neurotropin3-i showed:
-significant analgesia across all measures
-improvement in functional measures and PGA for all doses in a Ph2 RCT
- well tolerated
Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future
@RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU
sheila RHEUMarampa ( View Tweet)
